Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1374667-68-1

Post Buying Request

1374667-68-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1374667-68-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1374667-68-1 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,3,7,4,6,6 and 7 respectively; the second part has 2 digits, 6 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1374667-68:
(9*1)+(8*3)+(7*7)+(6*4)+(5*6)+(4*6)+(3*7)+(2*6)+(1*8)=201
201 % 10 = 1
So 1374667-68-1 is a valid CAS Registry Number.

1374667-68-1Downstream Products

1374667-68-1Relevant articles and documents

Discovery of 8-Trifluoromethyl-3-cyclopropylmethyl-7-[(4-(2,4-difluorophenyl)-1-piperazinyl)methyl]-1,2,4-triazolo[4,3-a]pyridine (JNJ-46356479), a Selective and Orally Bioavailable mGlu2 Receptor Positive Allosteric Modulator (PAM)

Cid, Jose María,Tresadern, Gary,Vega, Juan Antonio,De Lucas, Ana Isabel,Del Cerro, Alcira,Matesanz, Encarnación,Linares, María Lourdes,García, Aránzazu,Iturrino, Laura,Pérez-Benito, Laura,Macdonald, Gregor J.,Oehlrich, Daniel,Lavreysen, Hilde,Peeters, Luc,Ceusters, Marc,Ahnaou, Abdellah,Drinkenburg, Wilhelmus,Mackie, Claire,Somers, Marijke,Trabanco, Andrés A.

, p. 8495 - 8507 (2016/10/03)

Positive allosteric modulators of the metabotropic glutamate 2 receptor have generated great interest in the past decade. There is mounting evidence of their potential as therapeutic agents in the treatment of multiple central nervous system disorders. We have previously reported substantial efforts leading to potent and selective mGlu2 PAMs. However, finding compounds with the optimal combination of in vitro potency and good druglike properties has remained elusive, in part because of the hydrophobic nature of the allosteric binding site. Herein, we report on the lead optimization process to overcome the poor solubility inherent to the advanced lead 6. Initial prototypes already showed significant improvements in solubility while retaining good functional activity but displayed new liabilities associated with metabolism and hERG inhibition. Subsequent subtle modifications efficiently addressed those issues leading to the identification of compound 27 (JNJ-46356479). This new lead represents a more balanced profile that offers a significant improvement on the druglike attributes compared to previously reported leads.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1374667-68-1